此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

一项评估脂蛋白 (a) 降低 Pelacarsen (TQJ230) 对德国高脂蛋白血症 (a) 和已确诊心血管疾病患者每周脂蛋白单采术率的影响的多中心试验

2026年7月16日 更新者:Novartis Pharmaceuticals

一项随机、双盲、安慰剂对照、多中心试验,评估在德国接受每周脂蛋白单采术的高脂蛋白血症 (a) 和确定的心血管疾病患者使用 Pelacarsen (TQJ230) 治疗后与安慰剂相比脂蛋白单采术率的降低

III 期研究旨在检验以下假设:与安慰剂相比,用 pelacarsen (TQJ230) 80 mg Q4W 治疗可显着降低高脂蛋白血症患者的脂蛋白单采率 (a) 并确定目前在德国每周接受脂蛋白单采的心血管疾病。

研究概览

详细说明

迄今为止,脂蛋白单采术是在德国 Lp(a) 水平严重升高的患者中降低心血管 (CV) 风险的唯一批准的治疗选择。 脂蛋白单采术是一种昂贵、繁重且耗时的过程。 当前的研究 (CTQJ230A12302) 将调查 pelacarsen (TQJ230) 80 mg Q4W 治疗与安慰剂相比是否会降低高脂蛋白血症 (a) 和已确诊 CV 疾病患者的脂蛋白单采率

研究类型

介入性

注册 (实际的)

51

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Berlin、德国、13353
        • Novartis Investigative Site
      • Cloppenburg、德国、49661
        • Novartis Investigative Site
      • Erlangen、德国、91054
        • Novartis Investigative Site
      • Mainz、德国、55131
        • Novartis Investigative Site
      • Ulm、德国、89081
        • Novartis Investigative Site
    • Baden-Wurttemberg
      • Villingen-Schwenningen、Baden-Wurttemberg、德国、78052
        • Novartis Investigative Site
    • Bavaria
      • Munich、Bavaria、德国、81377
        • Novartis Investigative Site
      • Würzburg、Bavaria、德国、97080
        • Novartis Investigative Site
    • Hesse
      • Frankfurt am Main、Hesse、德国、60431
        • Novartis Investigative Site
    • Lower Saxony
      • Göttingen、Lower Saxony、德国、37075
        • Novartis Investigative Site
    • North Rhine-Westphalia
      • Düsseldorf、North Rhine-Westphalia、德国、42010
        • Novartis Investigative Site
      • Geilenkirchen、North Rhine-Westphalia、德国、52511
        • Novartis Investigative Site
    • Saxony
      • Dresden、Saxony、德国、01307
        • Novartis Investigative Site

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 80年 (成人、年长者)

接受健康志愿者

不

描述

纳入标准:

  • 目前在德国接受脂蛋白单采术分离 Lp(a) 的患者在筛选前每周 ≥ 12 个月,并且在随机分组前的过去 52 周内至少进行了 40 次治疗
  • 筛选时脂蛋白 (a) (Lp(a)) > 60 mg/dL
  • 自发性既往心肌梗死 (MI):筛查访视后 ≥ 3 个月至筛查访视前 ≤ 10 年,和/或
  • 缺血性中风:筛查访视后 ≥ 3 个月至筛查访视前 ≤ 10 年,和/或
  • 有临床意义的症状性外周动脉疾病 (PAD)

排除标准:

  • 不受控制的高血压
  • 心力衰竭纽约心脏协会 (NYHA) IV 级
  • 任何器官系统的恶性病史
  • 出血性中风或其他大出血史
  • 血小板计数
  • 活动性肝病或肝功能障碍
  • 显着的肾脏疾病
  • 孕妇或哺乳期妇女

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
实验性的:Pelacarsen (TQJ230)
Pelacarsen (TQJ230) 80 mg s.c. Q4W
Pelacarsen (TQJ230) 80 mg 皮下注射 Q4W
其他名称:
  • TQJ230
安慰剂比较:Placebo
Placebo to Pelacarsen s.c. Q4W
安慰剂对佩拉卡森
其他名称:
  • 安慰剂

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Rate of Lipoprotein Apheresis Sessions Performed Over 52 Weeks Normalized to the Weekly Lipoprotein Apheresis Schedule
大体时间:Up to Week 52
Rate (proportion) of apheresis sessions was calculated as the number of actual lipoprotein apheresis (LA) sessions received, divided by the number of planned LA sessions during the 52-week period, which is 52 for patients who completed all study visits, or pro-rated for those who discontinued early. This rate could range from 0 to 1, with 0 indicating that the patient had skipped all planned LA sessions, and 1 indicating that the patient had received all planned sessions. Multiple imputation for missing Lp(a) data was performed, and missing apheresis data was imputed.
Up to Week 52

次要结果测量

结果测量
措施说明
大体时间
Time to Lipoprotein Apheresis Avoidance
大体时间:From randomization up to Week 52
Lipoprotein apheresis avoidance is defined as at least 24 consecutive weeks of no lipoprotein apheresis until end of study.
From randomization up to Week 52
Number of Participants With Total Lipoprotein Apheresis Avoidance From Week 12 to Week 52
大体时间:Week 12 up to Week 52
Total lipoprotein apheresis avoidance is defined as no apheresis performed from Week 12 to Week 52.
Week 12 up to Week 52
Change From Baseline to Week 52 in the Log-transformed Lp(a) Reported as mg/dL
大体时间:Baseline, week 52
Week 52 / Baseline ratio in Lp(a) of pelacarsen (TQJ230) vs placebo reported as particle mass (mg/dL). Baseline Lp(a) was defined as the last non-missing pre-lipoprotein apheresis assessment prior to the first dose of randomized study drug.
Baseline, week 52
Change From Baseline to Week 52 in the Log-transformed Lp(a) Reported as Nmol/L
大体时间:Baseline, week 52
Week 52 / Baseline ratio in Lp(a) of pelacarsen (TQJ230) vs placebo reported as molar concentration (nmol/L). Baseline Lp(a) was defined as the last non-missing pre-lipoprotein apheresis assessment prior to the first dose of randomized study drug.
Baseline, week 52

其他结果措施

结果测量
措施说明
大体时间
Rate of Lipoprotein Apheresis Sessions From Week 12 to Week 52 and Week 24 to Week 52 Normalized to the Weekly Lipoprotein Apheresis Schedule
大体时间:Week 12 to 52, Week 24 to 52
Rate (proportion) of apheresis sessions is calculated using the following formula: the total number of apheresis sessions performed over the double-blinded treatment period/total weeks from Week12 to Week52 or total weeks from Week24 to Week52. Multiple imputation for missing Lp(a) data was performed and missing apheresis data were imputed.
Week 12 to 52, Week 24 to 52
Number of Participants With Total Lipoprotein Apheresis Avoidance From Week 24 to Week 52
大体时间:Week 24 to Week 52
Number of participants with no apheresis performed between week 24 to week 52.
Week 24 to Week 52
Time-averaged Lp(a) Levels Reported as mg/dL
大体时间:Baseline, Week 52
Time averaged Lp(a) levels were calculated as CAVG = CMIN + 0.73 × (CMAX-CMIN), where CMAX and CMIN are the immediate pre- and post-apheresis Lp(a) levels.
Baseline, Week 52
Time-averaged Lp(a) Levels Reported as Nmol/L
大体时间:Baseline, Week 52
Time averaged Lp(a) levels were calculated as CAVG = CMIN + 0.73 × (CMAX-CMIN), where CMAX and CMIN are the immediate pre- and post-apheresis Lp(a) levels.
Baseline, Week 52
Percentage Change in Total Cholesterol, LDL-C, High-density Lipoprotein-Cholesterol (HDL-C), Non-HDL-C, Very-low-density Lipoprotein-Cholesterol (VLDL-C), apoB and Triglycerides (Pre- Lipoprotein Apheresis) From Baseline to Week 52
大体时间:Baseline, Week 52
Evaluate the change in expanded lipid profile parameters measured in mg/dL
Baseline, Week 52
Change From Baseline to Week 52 in the Physical Health Summary Score for the SF-36 Questionnaire
大体时间:Baseline, Week 52

The Short Form-36 Physical Component Summary (SF-36 PCS) is an instrument to measure health-related quality of life among healthy patients and patients with acute and chronic conditions.

It consists of eight subscales (domains) that can be scored individually: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role- Emotional, and Mental Health. The outcome of the questionnaires in eight scales results in two summary scores, physical component and mental component, both ranging from 0 - 100.

Higher scores indicate a higher level of functioning. A positive change from baseline score indicates an improvement.

Baseline, Week 52
Change From Baseline to Week 52 in the Mental Health Summary Score for the SF-36 Questionnaire
大体时间:Baseline, Week 52

The Short Form-36 Physical Component Summary (SF-36 PCS) is an instrument to measure health-related quality of life among healthy patients and patients with acute and chronic conditions.

It consists of eight subscales (domains) that can be scored individually: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role- Emotional, and Mental Health. The outcome of the questionnaires in eight scales results in two summary scores, physical component and mental component, both ranging from 0 - 100.

Higher scores indicate a higher level of functioning. A positive change from baseline score indicates an improvement.

Baseline, Week 52
Patient Preference Questionnaire
大体时间:Baseline, Week 52
Participants were asked for their treatment preference between weekly lipoprotein apheresis or monthly self-injection. The number of participants that prefer each option at baseline and 52 weeks is reported.
Baseline, Week 52

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Novartis Pharmaceuticals、Novartis Pharmaceuticals

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2022年8月19日

初级完成 (实际的)

2025年1月28日

研究完成 (实际的)

2025年1月28日

研究注册日期

首次提交

2022年3月14日

首先提交符合 QC 标准的

2022年3月22日

首次发布 (实际的)

2022年3月31日

研究记录更新

最后更新发布 (实际的)

2026年7月17日

上次提交的符合 QC 标准的更新

2026年7月16日

最后验证

2026年7月1日

更多信息

与本研究相关的术语

其他研究编号

  • CTQJ230A12302
  • 2021-003059-41 (EudraCT编号)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

诺华致力于与合格的外部研究人员共享患者水平数据的访问权限,并支持符合条件的研究的临床文件。 这些请求由独立审查小组根据科学价值审查和批准。 所提供的所有数据均已匿名处理,以根据适用的法律法规尊重参与试验的患者的隐私。 该试验数据的可用性是根据 www.clinicalstudydatarequest.com 上描述的标准和过程

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅